Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis Portfolio News / By Karina Tin March 25, 2020 Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Portfolio News / By Karina Tin March 23, 2021 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Read More »
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dematitis Portfolio News / By Karina Tin March 22, 2021 RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dematitis Read More »
Carmot Therapeutics expands leadership team with appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D Portfolio News / By Karina Tin March 16, 2021 Carmot Therapeutics expands leadership team with appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D Read More »
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers Portfolio News / By Karina Tin March 16, 2021 Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers Read More »
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results Portfolio News / By Karina Tin March 11, 2021 RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results Read More »
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin March 9, 2021 Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results Portfolio News / By Karina Tin March 4, 2021 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results Read More »
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin March 2, 2021 Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Read More »
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer Portfolio News / By Karina Tin March 2, 2021 NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer Read More »
